Document Express Naica Digital PCR Technology for Detection of PIK3CA Mutations in Plasma

Current status of breast cancer

The global incidence of breast cancer has been on the rise since the late 1970s

Studies have found that PIK3CA mutations occur in approximately 20%-40% of early breast cancer (eBC), and in HR+/Her2-eBC patients, PIK3CA mutations are associated with a good prognosis

PIK3CA mutant HR+/Her2-mBC patients have a poor prognosis and are resistant to chemotherapy.

Methods and patients

A total of 649 mBC patients from the SAFIR02 trial (NCT02299999) were selected and the available mutation profiles were selected for result analysis

Finally, the prognostic value of PIK3CA mutations in plasma samples (n=44) in chemotherapy was evaluated by next-generation sequencing methods and digital PCR methods

result

▪ 28% of HR+/Her2- tumors and 10% of TNBC have PIK3CA mutations

The level of PIK3CA in plasma described in the article was detected by digital PCR.

Naica Digital PCR Platform

The Naica digital PCR technology of French Stilla Technologies has unique advantages in nucleic acid detection

Journal Introduction

The main focus areas of ANNALS OF ONCOLOGY include: systemic anti-cancer treatments (with special attention to molecular targeted drugs and new immunotherapies), randomized trials (including negative trials), top-level guidelines, and current emergence as a key component of personalized medicine New fields such as molecular pathology, bioinformatics, modern statistics and biotechnology

Original link:

Digital PCR School

In order to facilitate everyone to learn digital PCR technology better, the Gene-π digital PCR school developed by the French company Stilla Technologies will interpret digital PCR technology for you in an all-round way, which can realize the advancement from novice to expert, and is suitable for all digital PCR technologies.

Beijing Shenlanyun Biotechnology Co.